Q-omics provides the consensus-scored IMMP2L profile across patient tissues and cancer cell-line models. IMMP2L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, IMMP2L is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, IMMP2L RNA expression shows 18,387 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where IMMP2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IMMP2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IMMP2L survival associations across molecular data types. IMMP2L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IMMP2L RNA expression–survival associations across cancer types. High IMMP2L expression shows unfavorable associations in HNSC, CESC, LUAD, SCLC and LUSC, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for IMMP2L RNA expression.
This table summarizes IMMP2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for IMMP2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IMMP2L shows lower tumor expression in KICH, UCEC, BLCA and BRCA and higher tumor expression in LIHC and COAD. The KICH box plot shows higher IMMP2L RNA expression in normal versus tumor tissue (log2 FC = −1.330, t-test p < 0.001).
This table shows molecular features associated with IMMP2L in patient tissues and cancer cell lines. In patient samples, IMMP2L shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, IMMP2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
